I3 Analytics' ClinicalTrials Navigator Sees A New Dawn For Multiple Sclerosis ... Daily Markets In addition to the aforementioned drugs that are pending FDA approval, there are several promising therapies in the later stages of clinical development at other biopharma heavyweights (such as Novartis' BAF312, Roche's repurposed Daclizumab, Nuron ... |
